中医综合疗法干预吸烟的IS患者疗效指标及IS大鼠炎症机制的研究
|
摘要
动脉粥样硬化和缺血中风存在炎症反应、基质金属蛋白酶活性的改变。吸烟是脑血管病的危险因素,文献表明：吸烟通过炎症反应、促血栓作用、及改变基质金属蛋白酶活性等途径,导致动脉粥样硬化发生、发展及心脑血管事件的发生。因此,吸烟与中风预后有一定的相关性。十五课题表明,中医综合治疗方案切中中风病情、疗效确切,文章临床试验将研究此方案对缺血中风吸烟患者疗效评价指标的影响；益脑康胶囊是此法下产生的治疗缺血中风的有效方药,文章动物实验将探讨益脑康胶囊对动脉粥样硬化性缺血中风大鼠炎症反应机制的影响。
临床试验
目的
中医综合疗法对吸烟的缺血中风患者疗效指标的影响
方法
病例来源于国家科技十五攻关项目的受试患者,以其中的吸烟患者和不吸烟患者为研究对象,探讨中医综合方案(A方案)和单纯西医治疗方案(B方案)对上述两种人群缺血中风疗效评价指标：脑卒中3个层次评定量表(残损水平：NIH量表、残疾水平：BI量表、残障水平：MRS量表)和生活质量量表(SS-QOL量表)与相应时点中医证候要素评价量表(SS-TCM量表)变化的影响。结果
1、对于缺血中风吸烟患者：A、B方案对患者第7天、14天及21天NIH量表的影响均无统计学差异,P值分别为(0.623、0.314、0.199)。A、B方案对患者第21天、60天及90天BI量表、MRS量表的影响均无统计学差异,P值分别为(0.415、0.650、0.190)、(0.092、0.128、0.157)。A、B方案对患者第14天、21天、60天及90天SS-QOL量表的影响均无统计学差异,P值分别为(0.587、0.639、0.783、0.437)。A、B方案对患者第7天、14天、21天、60天及90天SSTCM积分对生活影响评分的影响均无统计学差异,P值分别为(0.268、0.595、0.902、0.378、0.176)。
2、对于缺血中风不吸烟患者：A、B方案对患者第7天、14天及21天NIH量表的影响均无统计学差异,P值分别为(0.933、0.315、0.109)。A、B方案对患者第21天、60天及90天BI量表的影响均无统计学差异,P值分别为(0.915、0.505、0.091)。A、B方案对患者第21天、60天MRS量表的影响均无统计学差异,P值分别为(0.433、0.285),对第90天MRS量表的影响有统计学意义,P值为0.033。A、B方案对患者第14天、21天、60天及90天SS-QOL量表的影响均无统计学差异,P值分别为(0.914、0.648、0.388、0.283)。A、B方案对患者第7天、14天、21天、60天SSTCM积分对生活影响评分的影响均无统计学差异,P值分别为(0.693、0.061、0.106、0.060),对第90天SSTCM积分对生活影响评分的影响均有统计学差异,P值为0.005。
结论
1、对于缺血中风吸烟患者,在现有的观察期限内,中医综合方案和单纯西医方案对患者疗效评价指标的影响相当,但是随着时间的延长,相比较单纯西医方案,中医综合方案有提高患者疗效愈加明显的趋势。
2、对于缺血中风不吸烟患者,在现有的观察期限内,中医综合方案改善患者第90天残障能力(MRS量表评分)、第90天SSTCM积分对生活影响评分的能力优于单纯西医方案,对其它疗效评价指标的影响相当,但是随着时间的延长,相比较单纯西医方案,中医综合方案有提高患者疗效愈加明显的趋势。
3、从研究人群的一般特征及指标选取及评价时间点来看,相比较单纯西医方案,中医综合方案的优势在于：对具有伴发心脏病、糖尿病等慢性基础病、年龄相对较大、不吸患者有较好疗效,并且此疗效在一些随访时间较长的量表中显示更加明显。
动物实验
目的
探讨益脑康胶囊对动脉粥样硬化性急性缺血中风大鼠脑组织MMP-9、TIMP-1活性、ICAM-1表达；血液ICAM-1含量的影响。
方法
115只大鼠随机分为正常组、动脉粥样硬化组(AS组)、急性中风组、预防用药组、益脑康组、立普妥组。建立动脉粥样硬化叠加急性缺血中风大鼠复合模型,采取预防性用药与治疗性用药相结合的方式灌胃治疗,预防用药组灌胃治疗贯穿整个造模前后,益脑康组和立普妥组在中风模型成功后灌胃治疗1周。通过观察用药后大鼠实验室检测项目(脑组织MMP-9、TIMP-1活性的测定、脑组织及主动脉ICAM-1的表达、血液ICAM-1含量的测定、脑组织含水量测定等)的变化,探讨益脑康胶囊对上述检测项目的影响。
结果
1、与正常组比较,动脉粥样硬化组大鼠血液中ICAM-1含量显著升高(P<0.01),主动脉ICAM-1的表达增强。
2、与动脉粥样硬化组比较,中风模型成功时,大鼠血液中ICAM-1含量显著升高(P<0.01),脑组织ICAM-1的表达增强。
3、与中风模型成功时比较,中风后1周,中风模型组大鼠血液中ICAM-1含量显著升高(P<0.01),脑组织ICAM-1的表达增强。治疗1周后,与中风组相比,预防组、益脑康组、立普妥组大鼠血液中ICAM-1的含量均显著降低(P<0.01),脑组织ICAM-1的表达减弱；预防组、益脑康组、立普妥组组间比较,大鼠血液中ICAM-1的含量无差异(P>0.05)。而与中风模型成功时比较,预防组、益脑康组、立普妥组大鼠血液中ICAM-1的含量无差异(P>0.05)。
4、各组大鼠脑组织MMP-9活性的比较：中风治疗1周后,与正常组比较,中风组、预防组、益脑康组、立普妥组大鼠脑组织MMP-9的活性均显著升高(P<0.01)；与中风组比较,预防组、益脑康组、立普妥组大鼠脑组织MMP-9的活性均显著降低(P<0.01)；预防组、益脑康组、立普妥组组间比较,大鼠脑组织MMP-9的活性无差异(P>0.05)。
5、各组大鼠脑组织TIMP-1活性的比较：中风治疗1周后,与正常组比较,预防组、益脑康组、立普妥组大鼠脑组织TIMP-1的活性均显著升高(P<0.01),中风组大鼠脑组织TIMP-1的活性无差异(P>0.05)；与中风组比较,预防组、益脑康组、立普妥组大鼠脑组织TIMP-1的活性均显著升高(P<0.01)；预防组、益脑康组、立普妥组组间比较,大鼠脑组织TIMP-1的活性无差异(P>0.05)。
6、中风治疗1周后,与中风组比较,预防组、益脑康组、立普妥组脑组织含水量明显下降(P<0.01)；预防组、益脑康组、立普妥组组间比较,脑组织含水量差异无统计学意义。
结论
1、动脉粥样硬化和缺血中风存在炎症反应。
2、益脑康胶囊能够有效降低动脉粥样硬化性缺血中风大鼠血液ICAM-1的含量。
3、益脑康胶囊具有降低动脉粥样硬化性缺血中风大鼠脑组织MMP-9活性、升高脑组织TIMP-1活性的作用。
4、益脑康胶囊具有降低动脉粥样硬化性缺血中风大鼠脑组织含水量的作用。
5、益脑康胶囊抑制动脉粥样硬化性缺血中风大鼠炎症反应、减轻脑水肿的可能机制是：降低血液中ICAM-1含量以及降低脑组织MMP-9活性、升高TIMP-1的活性。
There is inflammatory response and changes of matrix metalloproteinase activity in atherosclerosis and ischemic stroke. Smoking is a risk factor of cerebrovascular disease, literature shows that smoking leads to atherosclerotic and cardiovascular and cerebrovascular diseases through inflammatory response, effect of promoting thrombosis, changes of matrix metalloproteinase activity and so on. Thus, there is some correlation between smoking and the prognosis of stroke. The fifteenth project-research shows that integrated TCM therapy hit the stroke disease and do good effect. The clinical trail of paper will study the influence of the integrated TCM therapy on outcome assessments indexes. Yi Naokang capsule is an effective effective prescriptions in the treatment of ischemic stroke resulting from above-mentioned therapeutic theory. The animal experiment of paper will investigate the influence of Yi Naokang capsual on inflammatory reaction about rats with atherosclerotic ischemic stroke.
The clinical trail
Objective
The influence of the integrated TCM therapy on outcome assessments indexes about smoking patients with ischemic stroke.
Method
The cases were from patients in fifteenth project-research, selecting the smoking and non-smoking patients to investigate the influence of integrated TCM therapy(A plan) and simple western medicine program(B plan) on outcome assessments indexes for ischemic stroke, Namely three measuring scale levels about the disease(NIH, BI, MRS, SS-QOLand SS-TCM).
Result
1. For smoking patients with ischemic stroke:There is no statistical difference about score NIH in patients treated with A and B plan respectively on 7,14 and 21 days after entering the group. The statistical P are(0.623,0.314,0.199).There is no statistical difference about score BI and MRS in patients treated with A and B plan respectively on 21,60 and 90 days after entering the group. The statistical P are(0.092,0.128,0.157). There is no statistical difference about score SS-QOL in patients treated with A and B plan respectively on 14,21,60 and 90 days after entering the group. The statistical P are(0.587,0.639,0.783,0.437). There is no statistical difference about score SS-QOL in patients treated with A and B plan respectively on 14,21,60 and 90 days after entering the group. The statistical P are (0.587,0.639,0.783,0.437). There is no statistical difference about score of SSTCM affecting life in patients treated with A and B plan respectively on 7,14,21,60 and 90 days after entering the group. The statistical P are (0.268,0.595,0.902,0.378,0.176).
2. For non-smoking patients with ischemic stroke:There is no statistical difference about score NIH in patients treated with A and B plan respectively on 7,14 and 21 days after entering the group. The statistical P are(0.933,0.315,0.109). There is no statistical difference about score BI in patients treated with A and B plan respectively on 21,60 and 90 days after entering the group. The statistical P are(0.915,0.505,0.091). There is no statistical difference about score MRS in patients treated with A and B plan respectively on 21 and 60 days after entering the group. The statistical P are(0.433,0.285). But there is statistical difference on the 90th day (P=0.033). There is no statistical difference about score SS-QOL in patients treated with A and B plan respectively on 14,21,60 and 90 days after entering the group. The statistical P are(0.914,0.648,0.388,0.283). There is no statistical difference about score of SSTCM affecting life in patients treated with A and B plan respectively on 7,14,21 and 60 days after entering the group. The statistical P are(0.693,0.061,0.106,0.060).But there is statistical difference on the 90th day(P=0.005).
Conclusion
1.For smoking patients with ischemic stroke:In the current observation period, the integrated TCM therapy and simple western medicine program have equivalent effects on outcome assessments indexes for patients. But with the time longer, compared with simple western medicine program, the integrated TCM therapy has the increasingly significant trend of improving the efficacy.
2. For non-smoking patients with ischemic stroke:In the current observation period, for improving the 90th score MRS and score of SSTCM affecting life, the integrated TCM therapy make better than simple western medicine program. But there are no differences of other outcome assessments indexes between A and B plans. With the time longer, compared with simple western medicine program, the integrated TCM therapy still has the increasingly significant trend of improving the efficacy.
3. According to the general characteristics of patients and the selection and time of evaluation about outcome assessments indexes, compared with simple western medicine program, the advantages of the integrated TCM therapy are that there is better efficacy for non-smoking ischemic stroke patients with heart disease, diabetes and other chronic underlying diseases, relatively older.The clinical effect shows more apparent in some scales with longer follow-up time.
Objective
To investigate the influence of Yi Naokang capsule on content of MMP-9, TIMP-1 and expression of ICAM-1 in brain tissue and the level of serum ICAM-1 about rats with atherosclerotic ischemic stroke.
Method
115 rats were divided into 6 groups randomly:normal group, arterioscl-erosis group, ischemic stroke group, preventive medication group, Yi Nao kang group and Lipitor group. Duplicating atherosclerotic ischemic stroke model, and the rats were administered by intragastric injection using preventive and therapeutic usage. Preventive medication group was irrigated the stomach once a day before and after modeling, Yi Naokang group and Lipitor group were irrigated the stomach once a day for seven days. At the last day of irrigating the stomach, observing the changes of experiment items(the activity of MMP-9 , TIMP-1 and the expression of ICAM-1 in brain tissue,the content of serum ICAM-1, and brain watercontent), investigating the influence of Yi Naokang capsule on forging index.
Result
1.Cmpared with normal group, the content of serum ICAM-1 was improved significantly(P<0.01)in arteriosclerosis group and the expression of ICAM-1 in aorta was more obviously.
2. Compared with arteriosclerosis group,the content of serum ICAM-1 was improved significantly(P<0.01)in ischemic stroke group and the exp-ression of ICAM-1 in brain tissue was more obviously.
3.The content of serum ICAM-1 was improved significantly(P<0.01)and the expression of ICAM-1 in brain tissue was obviously one week after ischemic stroke. One week at the end of treatment, compared with ischemic stroke group , the content of serum ICAM-1 was decreased significantly (P<0.01) in preventive medication group,Yi Naokang group and Lipitor group, and the expression of ICAM-1 in brain tissue was decline, but there is no statistical difference in the content of serum ICAM-lamong preven- tive medication group,Yi Naokang group and Lipitorgroup(P>0.05). Compared with ischemic stroke group one week before treatment, there is no statis- tical difference in the content of serum ICAM-lamong ischemic stroke group, preventive medication group, Yi Naokang group and Lipitor group (P>0.05).
4. The comparison of the activity of MMP-9 in brain tissue for each gr-oup:One week after treatment of stroke, compared with normal group, the act-ivity of MMP-9 in brain tissue was improved significantly(P<0.01)in pre-ventive medication group,Yi Naokang group and Lipitor group.At the end of treatment, compared with ischemic stroke group, the activity of MMP-9 in brain tissue decreased obviously(P<0.01)in preventive medication group, Yi Naokang group and Lipitor group,but there is no statistical difference(P>0.05)among preventive medication group, Yi Naokang group and Lipitor group.
5. The comparison of the activity of TIMP-1 in brain tissue for each group: One week after treatment of stroke, compared with normal group, the activity of TIMP-1 in brain tissue was improved significantly(P<0.01)in preventive medication group, Yi Naokang group and Lipitor group, but there is no statis-tical difference(P>0.05)in ischemic stroke group.At the end of treatment, compared with ischemic stroke group, the activity of TIMP-1 in brain tissue increased obviously(P<0.01)in preventive medication group, Yi Naokang group and Lipitor group, but there is no statistical difference(P>0.05)among pre-ventive medication group, Yi Naokang group and Lipitor group.
6. One week after treatment of stroke, compared with ischemic stroke group, the brain water content decreased obviously (P<0.01)in preventive medication group, Yi Nao kang group and Lipitor group,but there is no statis-tical difference(P>0.05)among preventive medication group, Yi Naokang group and Lipitor group.
Conclusion
1. Inflammatory responce exists between artherosclerosis and ischemic stroke.
2. Yi Nao kang capsule can reduce the content of serum ICAM-1 and Expression of ICAM-1 in brain tissue in rats with atherosclerotic ischemic stroke effectively.
3. Yi Nao kang capsule can reduce the activity of MMP-9 but enhance the activity of TIMP-1 in brain tissue in rats with atherosclerotic ischemic stroke effectively.
4. Yi Nao kang capsule can reduce brain water content in rats with Atherosclerotic ischemic stroke.
5.The possible mechanism of depressing inflammatory responce and cerebral edema by Yi Naokang capsule was that it can reduce the content of serum ICAM-1, the expression of ICAM-1 in brain tissue,the activity of MMP-9 in brain tissue and improve the activity of TIMP-1.
临床试验
目的
中医综合疗法对吸烟的缺血中风患者疗效指标的影响
方法
病例来源于国家科技十五攻关项目的受试患者,以其中的吸烟患者和不吸烟患者为研究对象,探讨中医综合方案(A方案)和单纯西医治疗方案(B方案)对上述两种人群缺血中风疗效评价指标：脑卒中3个层次评定量表(残损水平：NIH量表、残疾水平：BI量表、残障水平：MRS量表)和生活质量量表(SS-QOL量表)与相应时点中医证候要素评价量表(SS-TCM量表)变化的影响。结果
1、对于缺血中风吸烟患者：A、B方案对患者第7天、14天及21天NIH量表的影响均无统计学差异,P值分别为(0.623、0.314、0.199)。A、B方案对患者第21天、60天及90天BI量表、MRS量表的影响均无统计学差异,P值分别为(0.415、0.650、0.190)、(0.092、0.128、0.157)。A、B方案对患者第14天、21天、60天及90天SS-QOL量表的影响均无统计学差异,P值分别为(0.587、0.639、0.783、0.437)。A、B方案对患者第7天、14天、21天、60天及90天SSTCM积分对生活影响评分的影响均无统计学差异,P值分别为(0.268、0.595、0.902、0.378、0.176)。
2、对于缺血中风不吸烟患者：A、B方案对患者第7天、14天及21天NIH量表的影响均无统计学差异,P值分别为(0.933、0.315、0.109)。A、B方案对患者第21天、60天及90天BI量表的影响均无统计学差异,P值分别为(0.915、0.505、0.091)。A、B方案对患者第21天、60天MRS量表的影响均无统计学差异,P值分别为(0.433、0.285),对第90天MRS量表的影响有统计学意义,P值为0.033。A、B方案对患者第14天、21天、60天及90天SS-QOL量表的影响均无统计学差异,P值分别为(0.914、0.648、0.388、0.283)。A、B方案对患者第7天、14天、21天、60天SSTCM积分对生活影响评分的影响均无统计学差异,P值分别为(0.693、0.061、0.106、0.060),对第90天SSTCM积分对生活影响评分的影响均有统计学差异,P值为0.005。
结论
1、对于缺血中风吸烟患者,在现有的观察期限内,中医综合方案和单纯西医方案对患者疗效评价指标的影响相当,但是随着时间的延长,相比较单纯西医方案,中医综合方案有提高患者疗效愈加明显的趋势。
2、对于缺血中风不吸烟患者,在现有的观察期限内,中医综合方案改善患者第90天残障能力(MRS量表评分)、第90天SSTCM积分对生活影响评分的能力优于单纯西医方案,对其它疗效评价指标的影响相当,但是随着时间的延长,相比较单纯西医方案,中医综合方案有提高患者疗效愈加明显的趋势。
3、从研究人群的一般特征及指标选取及评价时间点来看,相比较单纯西医方案,中医综合方案的优势在于：对具有伴发心脏病、糖尿病等慢性基础病、年龄相对较大、不吸患者有较好疗效,并且此疗效在一些随访时间较长的量表中显示更加明显。
动物实验
目的
探讨益脑康胶囊对动脉粥样硬化性急性缺血中风大鼠脑组织MMP-9、TIMP-1活性、ICAM-1表达；血液ICAM-1含量的影响。
方法
115只大鼠随机分为正常组、动脉粥样硬化组(AS组)、急性中风组、预防用药组、益脑康组、立普妥组。建立动脉粥样硬化叠加急性缺血中风大鼠复合模型,采取预防性用药与治疗性用药相结合的方式灌胃治疗,预防用药组灌胃治疗贯穿整个造模前后,益脑康组和立普妥组在中风模型成功后灌胃治疗1周。通过观察用药后大鼠实验室检测项目(脑组织MMP-9、TIMP-1活性的测定、脑组织及主动脉ICAM-1的表达、血液ICAM-1含量的测定、脑组织含水量测定等)的变化,探讨益脑康胶囊对上述检测项目的影响。
结果
1、与正常组比较,动脉粥样硬化组大鼠血液中ICAM-1含量显著升高(P<0.01),主动脉ICAM-1的表达增强。
2、与动脉粥样硬化组比较,中风模型成功时,大鼠血液中ICAM-1含量显著升高(P<0.01),脑组织ICAM-1的表达增强。
3、与中风模型成功时比较,中风后1周,中风模型组大鼠血液中ICAM-1含量显著升高(P<0.01),脑组织ICAM-1的表达增强。治疗1周后,与中风组相比,预防组、益脑康组、立普妥组大鼠血液中ICAM-1的含量均显著降低(P<0.01),脑组织ICAM-1的表达减弱；预防组、益脑康组、立普妥组组间比较,大鼠血液中ICAM-1的含量无差异(P>0.05)。而与中风模型成功时比较,预防组、益脑康组、立普妥组大鼠血液中ICAM-1的含量无差异(P>0.05)。
4、各组大鼠脑组织MMP-9活性的比较：中风治疗1周后,与正常组比较,中风组、预防组、益脑康组、立普妥组大鼠脑组织MMP-9的活性均显著升高(P<0.01)；与中风组比较,预防组、益脑康组、立普妥组大鼠脑组织MMP-9的活性均显著降低(P<0.01)；预防组、益脑康组、立普妥组组间比较,大鼠脑组织MMP-9的活性无差异(P>0.05)。
5、各组大鼠脑组织TIMP-1活性的比较：中风治疗1周后,与正常组比较,预防组、益脑康组、立普妥组大鼠脑组织TIMP-1的活性均显著升高(P<0.01),中风组大鼠脑组织TIMP-1的活性无差异(P>0.05)；与中风组比较,预防组、益脑康组、立普妥组大鼠脑组织TIMP-1的活性均显著升高(P<0.01)；预防组、益脑康组、立普妥组组间比较,大鼠脑组织TIMP-1的活性无差异(P>0.05)。
6、中风治疗1周后,与中风组比较,预防组、益脑康组、立普妥组脑组织含水量明显下降(P<0.01)；预防组、益脑康组、立普妥组组间比较,脑组织含水量差异无统计学意义。
结论
1、动脉粥样硬化和缺血中风存在炎症反应。
2、益脑康胶囊能够有效降低动脉粥样硬化性缺血中风大鼠血液ICAM-1的含量。
3、益脑康胶囊具有降低动脉粥样硬化性缺血中风大鼠脑组织MMP-9活性、升高脑组织TIMP-1活性的作用。
4、益脑康胶囊具有降低动脉粥样硬化性缺血中风大鼠脑组织含水量的作用。
5、益脑康胶囊抑制动脉粥样硬化性缺血中风大鼠炎症反应、减轻脑水肿的可能机制是：降低血液中ICAM-1含量以及降低脑组织MMP-9活性、升高TIMP-1的活性。
There is inflammatory response and changes of matrix metalloproteinase activity in atherosclerosis and ischemic stroke. Smoking is a risk factor of cerebrovascular disease, literature shows that smoking leads to atherosclerotic and cardiovascular and cerebrovascular diseases through inflammatory response, effect of promoting thrombosis, changes of matrix metalloproteinase activity and so on. Thus, there is some correlation between smoking and the prognosis of stroke. The fifteenth project-research shows that integrated TCM therapy hit the stroke disease and do good effect. The clinical trail of paper will study the influence of the integrated TCM therapy on outcome assessments indexes. Yi Naokang capsule is an effective effective prescriptions in the treatment of ischemic stroke resulting from above-mentioned therapeutic theory. The animal experiment of paper will investigate the influence of Yi Naokang capsual on inflammatory reaction about rats with atherosclerotic ischemic stroke.
The clinical trail
Objective
The influence of the integrated TCM therapy on outcome assessments indexes about smoking patients with ischemic stroke.
Method
The cases were from patients in fifteenth project-research, selecting the smoking and non-smoking patients to investigate the influence of integrated TCM therapy(A plan) and simple western medicine program(B plan) on outcome assessments indexes for ischemic stroke, Namely three measuring scale levels about the disease(NIH, BI, MRS, SS-QOLand SS-TCM).
Result
1. For smoking patients with ischemic stroke:There is no statistical difference about score NIH in patients treated with A and B plan respectively on 7,14 and 21 days after entering the group. The statistical P are(0.623,0.314,0.199).There is no statistical difference about score BI and MRS in patients treated with A and B plan respectively on 21,60 and 90 days after entering the group. The statistical P are(0.092,0.128,0.157). There is no statistical difference about score SS-QOL in patients treated with A and B plan respectively on 14,21,60 and 90 days after entering the group. The statistical P are(0.587,0.639,0.783,0.437). There is no statistical difference about score SS-QOL in patients treated with A and B plan respectively on 14,21,60 and 90 days after entering the group. The statistical P are (0.587,0.639,0.783,0.437). There is no statistical difference about score of SSTCM affecting life in patients treated with A and B plan respectively on 7,14,21,60 and 90 days after entering the group. The statistical P are (0.268,0.595,0.902,0.378,0.176).
2. For non-smoking patients with ischemic stroke:There is no statistical difference about score NIH in patients treated with A and B plan respectively on 7,14 and 21 days after entering the group. The statistical P are(0.933,0.315,0.109). There is no statistical difference about score BI in patients treated with A and B plan respectively on 21,60 and 90 days after entering the group. The statistical P are(0.915,0.505,0.091). There is no statistical difference about score MRS in patients treated with A and B plan respectively on 21 and 60 days after entering the group. The statistical P are(0.433,0.285). But there is statistical difference on the 90th day (P=0.033). There is no statistical difference about score SS-QOL in patients treated with A and B plan respectively on 14,21,60 and 90 days after entering the group. The statistical P are(0.914,0.648,0.388,0.283). There is no statistical difference about score of SSTCM affecting life in patients treated with A and B plan respectively on 7,14,21 and 60 days after entering the group. The statistical P are(0.693,0.061,0.106,0.060).But there is statistical difference on the 90th day(P=0.005).
Conclusion
1.For smoking patients with ischemic stroke:In the current observation period, the integrated TCM therapy and simple western medicine program have equivalent effects on outcome assessments indexes for patients. But with the time longer, compared with simple western medicine program, the integrated TCM therapy has the increasingly significant trend of improving the efficacy.
2. For non-smoking patients with ischemic stroke:In the current observation period, for improving the 90th score MRS and score of SSTCM affecting life, the integrated TCM therapy make better than simple western medicine program. But there are no differences of other outcome assessments indexes between A and B plans. With the time longer, compared with simple western medicine program, the integrated TCM therapy still has the increasingly significant trend of improving the efficacy.
3. According to the general characteristics of patients and the selection and time of evaluation about outcome assessments indexes, compared with simple western medicine program, the advantages of the integrated TCM therapy are that there is better efficacy for non-smoking ischemic stroke patients with heart disease, diabetes and other chronic underlying diseases, relatively older.The clinical effect shows more apparent in some scales with longer follow-up time.
Objective
To investigate the influence of Yi Naokang capsule on content of MMP-9, TIMP-1 and expression of ICAM-1 in brain tissue and the level of serum ICAM-1 about rats with atherosclerotic ischemic stroke.
Method
115 rats were divided into 6 groups randomly:normal group, arterioscl-erosis group, ischemic stroke group, preventive medication group, Yi Nao kang group and Lipitor group. Duplicating atherosclerotic ischemic stroke model, and the rats were administered by intragastric injection using preventive and therapeutic usage. Preventive medication group was irrigated the stomach once a day before and after modeling, Yi Naokang group and Lipitor group were irrigated the stomach once a day for seven days. At the last day of irrigating the stomach, observing the changes of experiment items(the activity of MMP-9 , TIMP-1 and the expression of ICAM-1 in brain tissue,the content of serum ICAM-1, and brain watercontent), investigating the influence of Yi Naokang capsule on forging index.
Result
1.Cmpared with normal group, the content of serum ICAM-1 was improved significantly(P<0.01)in arteriosclerosis group and the expression of ICAM-1 in aorta was more obviously.
2. Compared with arteriosclerosis group,the content of serum ICAM-1 was improved significantly(P<0.01)in ischemic stroke group and the exp-ression of ICAM-1 in brain tissue was more obviously.
3.The content of serum ICAM-1 was improved significantly(P<0.01)and the expression of ICAM-1 in brain tissue was obviously one week after ischemic stroke. One week at the end of treatment, compared with ischemic stroke group , the content of serum ICAM-1 was decreased significantly (P<0.01) in preventive medication group,Yi Naokang group and Lipitor group, and the expression of ICAM-1 in brain tissue was decline, but there is no statistical difference in the content of serum ICAM-lamong preven- tive medication group,Yi Naokang group and Lipitorgroup(P>0.05). Compared with ischemic stroke group one week before treatment, there is no statis- tical difference in the content of serum ICAM-lamong ischemic stroke group, preventive medication group, Yi Naokang group and Lipitor group (P>0.05).
4. The comparison of the activity of MMP-9 in brain tissue for each gr-oup:One week after treatment of stroke, compared with normal group, the act-ivity of MMP-9 in brain tissue was improved significantly(P<0.01)in pre-ventive medication group,Yi Naokang group and Lipitor group.At the end of treatment, compared with ischemic stroke group, the activity of MMP-9 in brain tissue decreased obviously(P<0.01)in preventive medication group, Yi Naokang group and Lipitor group,but there is no statistical difference(P>0.05)among preventive medication group, Yi Naokang group and Lipitor group.
5. The comparison of the activity of TIMP-1 in brain tissue for each group: One week after treatment of stroke, compared with normal group, the activity of TIMP-1 in brain tissue was improved significantly(P<0.01)in preventive medication group, Yi Naokang group and Lipitor group, but there is no statis-tical difference(P>0.05)in ischemic stroke group.At the end of treatment, compared with ischemic stroke group, the activity of TIMP-1 in brain tissue increased obviously(P<0.01)in preventive medication group, Yi Naokang group and Lipitor group, but there is no statistical difference(P>0.05)among pre-ventive medication group, Yi Naokang group and Lipitor group.
6. One week after treatment of stroke, compared with ischemic stroke group, the brain water content decreased obviously (P<0.01)in preventive medication group, Yi Nao kang group and Lipitor group,but there is no statis-tical difference(P>0.05)among preventive medication group, Yi Naokang group and Lipitor group.
Conclusion
1. Inflammatory responce exists between artherosclerosis and ischemic stroke.
2. Yi Nao kang capsule can reduce the content of serum ICAM-1 and Expression of ICAM-1 in brain tissue in rats with atherosclerotic ischemic stroke effectively.
3. Yi Nao kang capsule can reduce the activity of MMP-9 but enhance the activity of TIMP-1 in brain tissue in rats with atherosclerotic ischemic stroke effectively.
4. Yi Nao kang capsule can reduce brain water content in rats with Atherosclerotic ischemic stroke.
5.The possible mechanism of depressing inflammatory responce and cerebral edema by Yi Naokang capsule was that it can reduce the content of serum ICAM-1, the expression of ICAM-1 in brain tissue,the activity of MMP-9 in brain tissue and improve the activity of TIMP-1.
引文
[1]饶明俐.中国脑血管病防治指南[M].北京：人民卫生出版社,2007,1：25.
[2]王艳,王伊龙,吴敌等.缺血性脑卒中危险因素及其控制与临床发病严重程度的关系[J].中国综合临床,2008,24(4)：347.
[3]Ovbiagele B, ChristoPher WJ, Jeffrey SL, et al. Effect of smoking status on outcome after acute iecheraic shoke. Imagm investigators[J]. CerebMas eular Diseases,2006,21(4):260-265.
[4]王建礼,商战平,王家富.巨噬细胞移动抑制因子与动脉粥样硬化[J].医学综述,2007,13(13)：967.
[5]Lin SG, Yu XY, et al. De novo exPression of macroPhage migration inhibitory factor in atherogenesis in rabbits [J]. Circ Res,2000,87(12):1202-1203Dmax.
[6]Newby AC, Zaltsman AB. Molecular mechanisms in intimal hyPerPlasia[J]. J Pathol,2000,190:300-309.
[7]Brown DL, Hibbs MS, Kearney M, et al. Identification of 92-KD gelatinase in human coronary atherosclerotic lesions.Association of active enzyme synthesis with unstable angina[J]. Circulation,1995,91:2125-2131.
[8]甘霖,李生伟,龚建平.TIMPs的结构、生物学功能研究进展[J].中华医学写作杂志,2004,11(19)：1673.
[9]张振海,张永波.基质金属蛋白酶组织抑制剂与动脉粥样硬化[J].中西医结合心脑血管病杂志,2008,6(3)：329.
[10]高峰,宋水江,吴继敏等.基质金属蛋白酶-9及其组织抑制物-1与颈动脉粥样斑块稳定性相关研究[J].中国病理生理杂志,2007,23(9)：1701-1702.
[11]赖世隆,郭新峰,梁伟雄等.中风病疗效评价指标体系的初步研究[J].中国中西医结合杂志,2004,24(3)：198.
[12]蔡业峰,付于,郭建文等.中医综合治疗方案对急性缺血性中风中医症征影响的研究[J].陕西中医,2007,28(8)：1041.
[13]魏艳静,韦再华,李淑敏.脑卒中危险因素研究[J].中国临床保健杂志,2006,8(1)： 82.
[14]王忠,张伯礼,申春娣.中风病中医危险因素研究——回顾性与现场研究资料的比较和分析[J].北京中医药大学学报,2002,25(5)：49.
[15]商洪才,张伯礼.中医中风病危险因素及先兆症(证)研究系统评[J].中国中医药信息杂志,2002,(9)：3.
[16]冉志军.中医对脑血管病高位因素的认识[J].辽宁中医药大学学报,2008,10(6)：
12-13.
[17]赵海滨,左俊岭.中风先兆高危因素的调查分析[J].上海中医药杂志,2002,36(10)：11-12.
[18]黄慧敏,王涛.炎症、动脉粥样硬化与缺血性卒中.国际脑血管病杂志,2007,15(6)：464.
[19]刘冉,郝洪军,孙伟平等.血清炎性标志物与缺血性脑血管病的关系[J].中国神经免疫学和神经病学杂志,2009,16(2)：128.
[20]田海军,马燕妮,李朝武.影响脑梗死患者预后的相关因素分析及血尿酸检测的意义[J].白求恩医学院学报,2007,5(1)：5.
[21]谈晓牧,刘建国,耿晓坤等.高同型半胱氨酸血症对缺血性脑卒中患者再发及死亡预后影响的随访研究[J].中国神经免疫学和神经病学杂志,2009,16(5)：325.
[22]胡英嗣.脑卒中患者血清LP(a)水平与病情及预后的关系[J].Modern PracticalMedicine,2003,15(7)：422.
[23]周永,黄怀宇,朱向阳.缺血性卒中早期神经功能恶化的临床特征和危险因素分析[J].南通大学学报,2007,27(5)：362.
[24]杜敢琴,黄丽娜,富奇志等.脑卒中预后的影响因素分析[J].中华神经医学杂志,2005,4(1)：57.
[25]丁则昱,李晓光,崔丽英等.影响脑梗死远期预后的各风险指标分析[J].中国卒中,2006,1(3)：183.
[26]赵丽宏,韩杰.缺血性脑卒中病因分型与临床预后的关系[J].中华老年心脑血管病杂志,2009,11(6)：428.
[27]刘学东.缺血性脑卒中预后及其影响因素的研究[D].西安：流行病与卫生统计学,2007.
[28]陈瑞珍,吴慧堑,陈晓君.缺血性脑卒中就诊时间对患者预后的影响及护理对策[J].现代临床护理,2009,8(1)：23.
[29]杨翠英,郑华光,王立英等.代谢综合征对急性脑梗死早期预后的影响[J].中国卒中杂志,2007,2(7)：581.
[30]SU Yongjing, ZHANG zhenlu, ZHANG Xiaoyan, et al. New-Onset constiPation after stroke:incidence, risk factors and imPact on the Prognosis of stroke[J]. Chin J Ment Dis:2006,32 (4):300.
[31]范文可,胡永善,陈文华等.影响脑卒中患者发病后6个月时综合功能的多因素分析[J].中华物理医学与康复杂志,2008,30(3)：176.
[32]郑杰,田瑞振,刘德山.动脉粥样硬化的中医致病论初探[J].云南中医学院学报,2008,31(2)：28-29.
[33]程翔,廖玉华.炎症与动脉粥样硬化[J].中华心血管病杂志,2004,32(5)：475-
477.
[34]赵胜,刘伏元.特异性免疫与动脉粥样硬化[J].心血管康复医学杂志,2008,1(6)：595.
[35]张韶辉,高东升.动脉粥样硬化与炎症及药物应用研究进展[J].心血管病学进展2007,28(6)：947.
[36]马琳.益气活血法治疗缺血中风恢复期30例小结[J].中医中药,2007,45(21)：76.
[37]董道明,秦振华.育阴通络法在中风恢复期的应用体会[J].甘肃中医,2005,18(11)：28.
[38]常富业,王永炎.中风病毒邪论[J].北京中医药大学学报,2004,27(1)：3-6.
[39]王志菲,唐希灿.脑缺血损伤的炎症反应及治疗策略展望[J].中国新药与临床杂志,2007,26(6)：454-455.
[40]周明学,徐浩,潘琳等.活血、益气、化痰中药对APoE基因敲除小鼠主动脉粥样硬化斑块炎症反应的影响[J].中国中医急症,2008,17(4)：496.
[41]张京春,陈可冀.瘀毒病机与动脉粥样硬化易损斑块相关的理论思考[J].中国中西医结合杂志,2008,28(4)：368.
[42]贾冬,杜佳林,向绍杰等.消栓通络精制胶囊药效学实验研究[J].中国中药杂志,2007,32(12)：1244.
[43]许宏霞,曹晓岚,王敏.对缺血性中风病急性期炎症反应的中西医认识[J].中西医结合心脑血管病杂志,2007,5(2)：156.
[44]HUANG J, UPADHYAY UM, TAMARGO RJ. Inflammation in stroke and focal cerebral ischemia[J].Surg Neurol,2006.66(3):232-245.
[45]ZHANG RL, CHOPP M, JIANG N, et al. Anti-intercellular adhesion mole cule-1 antibody reduces ischemic cell damage after transient but not P ermanent middle cerebral artery occlusion in the Wistar rat[J]. Stroke,1995,26(8): 1438-1442.
[46]MASADA T, HUA Y, Xl G, et al. Attenuation of intracerebral hemorrha ge and thrombin-induced brain edema by overexPression of interleukin-1 recePtor antagonist[J]. J Neurosurg,2001,95(4):680-686.
[47]KAWA1 N, OKAUCH1 M, MORISAKI K, et al. Effects of delayed intraische mic and Postischemic hyPothermia on a focal model of transient cerebral ischemia in rats[J]. Stroke,2000,31(8):1982-1989.
[48JBOROVIKOVA LV, IVANOVA S, ZHANG M, et al. Vagus nerve stimulation att enuates the systemic inflammatory resPonse to endotoxin[J]. Nature,2000,405 (6785):458-462.
[49]PAVLOV VA, WANG H, CZURA CJ, et al.The cholinergic anti-inflammato ry Pathway:a missing link in neuroimmunomodulation[J]. Mol Med,2003,9(5-8): 125-134.
[50]TRACEY KJ. The inflammatory reflex[J]. Nature,2002,420(6917):853-859.
[51]TRACEY KJ, CZURA CJ, IVANOVA S.Mind over immunity[J]. FASEB J,2001, 15(9):1575-1576.
[52]CZURA CJ, FRIEDMAN SG, TRACEY KJ. Neural inhibition of inflammation:the cholinergic anti-inflammatory Pathway[J].J Endotoxin Res,2003,9(6): 409-413.
[53]马斌,高颖.脑卒中结局评价及建立病证结合临床评价模式的研究设想[J].中国临床康复,2006,35(10)：155.
[54]张伯礼,王玉来,高颖等.中风病急性期综合治疗方案研究与评价—附522例临床研究报告[J].中国危重病急救医学,2005,17(5)：263.
[55]老鹰荣,郭新峰,赖世隆等.不同维度多个量表对脑卒中恢复期评价的比较[J].中国临床康复,2005,9(29)：7.
[56]张振强,荆志伟,周红霞等.用世界卫生组织生存质量量表评价中风患者的生存质量[J].中国中医药信息杂志,2005,12(11)：18.
[57]高颖,马斌.中风病结局评价及病证结合临床评价标准的研究[C].中华中医药学会内科分会2007年学术年会论文集,2007,11：76.
[58]FruhwaldS, RelationshiP between dePression, anxiety and quality of life: A study of stroke Patients comPared to chronic low back Pain a nd myocardial ischemia Patients[J]. PsychoPathology,2001,34(1):5.
[59]张跃文,杨传东,周凤龙.中风中西医疗效评价之比较[J].中国社区医师·医学专业半月刊,2008,10(1)：9.
[60]金杰.中医治疗缺血性中风124例疗效对比观察[J].河南中医,2004,25(10)：42.
[61]Duncan PW, Jorgensen HS, Wade DT. Outcome measures in acute stroke trials: a systematic review and some recommendations to imProve Practice[J]. Stroke,2000,31(6):1434.
[62]杨鹏远,芮耀诚,焦亚斌.动脉粥样硬化大鼠实验模型的建立[J].第二军医大学学报,2003,24(7)：802-803.
[63]顾国军,黄振兴,陶凯忠等.HBO对内皮素-1诱导的大鼠局灶性脑缺血模型的疗效观察[J].第二军医大学学报,2006,27(10)：1135.
[64]吴浩,吉训明,赵喜庆等.改良大鼠MCAO模型的建立[J].中华实验外科杂志,2006,23(12)： 1554.
[65]许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4)：230.
[66]刘茂才,黄燕,卢明.中医脑病临证证治[M].广东.广东人民出版社,2006,1：110-122.
[67]刘英芹.粘附分子与缺血性脑损伤的研究进展[J].国外医学临床生物化学与检验学分册,2005,26(10)：703-704.
[68]庞霞,李平.炎症与不稳定动脉粥样硬化斑块[J].医学综述,2008,14(4)：539.
[69]孙平,陈文强,李宗信等.中西医干预动脉粥样硬化ICAM-1表达的研究进展[J].安徽中医学院学报,2007,26(3)：62.
[70]DaviesMJ, Gordon Gearing AJ. The exPression of the adhesion molecule ICAM-1, VCAM-1, PECAM-1 and E-selectin in human atherogenesis[J]. J Pathol ,1993,171(3):223-229.
[71]Daniel S The neuroPathology and neurochemistry of multiP le system atroPhy. InMathias C, Bannister R, eds Autonomic failure atextbook of clinical disorders of the autonomic nervous system[M]. Oxford:Oxford University Press,1999:321-328.
[72]DeGraba TJ, Siren AL, Penix L, et al. Increased Endothelial ExPression of Interce-llular Molecule-1 in SymPtomatic Versus AsymP tomatic Human Caro-tid Athero-sclerotic Plaque[J]. Stroke,1998,29(7):1405-1410.
[73]AsanoriAikawa, Peter Libby. The vulnerable atherosclerotic Plaque:Pathohen-esis and theraPeutic aPProach [J]. Cardio Vascular Pathology,2004,13(3): 125-138.
[74]Nageh MF, Sandberg ET, Marotti KR, et al. Deficiency of inflammatory cell adhesion molecules Protects against atherosclerosis in mice[J].Arterio-scler Thromb Vasc Biol,1997,17(8):1517-1520.
[75]付素洁,邱伟庆,尤可.中风恢复期病机及辨治进展[J].河南中医学院学报,2005,20(5)：86-87.
[76]祝维峰,周迎春,冯学功等.邵念方教授治疗中风病特色浅述[J].中国中医急症,1997,6(6)：274-275.
[77]Li JC, Zhou HD, Deng J, Wang YJ, Zhang M. A study of relation between changes in serum soluble intercellular adhesion molecule and infarction volume in Patients with acute cerebral infarction. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue[J].2008,20(11):660-2.
[78]Rallidis LS, Zolindaki MG, Vikelis M, Kalivak, et al. Elevated soluble inter-cellular adhesion molecule-1 levels are associated with Poor short-term
Prognosis in middle-aged Patients with acute ischaemic stroke. Int J Car-diol[J].2009,132(2):216-20.
[79]Simundic AM, Basic V, ToPic E, et al. Soluble adhesion molecules in acute ischemic stroke. Clin Invest Med [J].2004,27(2):86-92.
[80]蔡洪信,郝芳,夏作理.ICAM-1与脑缺血再灌注损伤研究进展.中国微循环[J].2005,9(5)：364.
[81]陈燕,陈慧.基质金属蛋白酶-9与易损斑块[J].心血管康复医学杂志,2007,16(1)： 96.
[82]王强,王毅.通脉胶囊对动脉粥样硬化斑块稳定性影响的实验研究[J].中成药,2004,26(9)：734.
[83]刘金来,朱强锋,郝宝顺.通心络血清对U937单核巨噬细胞MMP-9及TIMP-1表达与分泌的影响[J].南方医科大学学报,2008,28(9)：1706.
[84]金华.和中化痰活血法治疗缺血性中风恢复期及后遗症期的临床研究[J].甘肃中医,2000,13(3)：55-57.
[85]Yallg Y, Estrada EY, ThomPson JF, et al. Matrix metalloProteinasemediated disruption of tight junction Proteins in cerebral vessels is reversed by synthetic matrix melalloProteinase inhibitor in focal ischemia in rat[J]. J Cereb Blood Flow Metab,2007,27:697-709.
[86]麻志恒,魏国俊.中风恢复期从脾论治[J].甘肃中医学院学报,2001,18(1)：10-11.
[87]顾晔,刘振国.MMP-9与脑梗死出血性转化及研究进展[J].中国临床神经科学2008,16(4)：428.
[88]Lucivero V, Prontera M, MezzaPesa DM, et al. Different roles of matrix metalloProteinases-2 and-9 after human ischaemic stroke[J]. Neurol Sci, 2007,28:165-170.
[89]Rosell A, Alvarez-Sabin J, Arenillas JF, et al. A matrix metalloProteinase Protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human [J]. Stroke,2005, 36:1415-1420.
[90]Barr TL, Latour LL, Lee KY, et al. Blood-brain barrier disruPtion in humans is indePendently associated with increased matrixmetalloProteinase-9[J] .Stroke,2010,41(3):123-8.
[91]陶定波,姜秀丽,雷阳等.血清基质金属蛋白酶9和组织基质金属蛋白酶抑制剂1与急性脑梗死的临床关系[J].中华老年心脑血管病杂志,2009年10月第11卷第10期：777.
[92]冯民,张梅,张运等.吸烟与动脉粥样硬化的关系[J].中国动脉硬化杂志,2006,14(11)：1006.
[2]王艳,王伊龙,吴敌等.缺血性脑卒中危险因素及其控制与临床发病严重程度的关系[J].中国综合临床,2008,24(4)：347.
[3]Ovbiagele B, ChristoPher WJ, Jeffrey SL, et al. Effect of smoking status on outcome after acute iecheraic shoke. Imagm investigators[J]. CerebMas eular Diseases,2006,21(4):260-265.
[4]王建礼,商战平,王家富.巨噬细胞移动抑制因子与动脉粥样硬化[J].医学综述,2007,13(13)：967.
[5]Lin SG, Yu XY, et al. De novo exPression of macroPhage migration inhibitory factor in atherogenesis in rabbits [J]. Circ Res,2000,87(12):1202-1203Dmax.
[6]Newby AC, Zaltsman AB. Molecular mechanisms in intimal hyPerPlasia[J]. J Pathol,2000,190:300-309.
[7]Brown DL, Hibbs MS, Kearney M, et al. Identification of 92-KD gelatinase in human coronary atherosclerotic lesions.Association of active enzyme synthesis with unstable angina[J]. Circulation,1995,91:2125-2131.
[8]甘霖,李生伟,龚建平.TIMPs的结构、生物学功能研究进展[J].中华医学写作杂志,2004,11(19)：1673.
[9]张振海,张永波.基质金属蛋白酶组织抑制剂与动脉粥样硬化[J].中西医结合心脑血管病杂志,2008,6(3)：329.
[10]高峰,宋水江,吴继敏等.基质金属蛋白酶-9及其组织抑制物-1与颈动脉粥样斑块稳定性相关研究[J].中国病理生理杂志,2007,23(9)：1701-1702.
[11]赖世隆,郭新峰,梁伟雄等.中风病疗效评价指标体系的初步研究[J].中国中西医结合杂志,2004,24(3)：198.
[12]蔡业峰,付于,郭建文等.中医综合治疗方案对急性缺血性中风中医症征影响的研究[J].陕西中医,2007,28(8)：1041.
[13]魏艳静,韦再华,李淑敏.脑卒中危险因素研究[J].中国临床保健杂志,2006,8(1)： 82.
[14]王忠,张伯礼,申春娣.中风病中医危险因素研究——回顾性与现场研究资料的比较和分析[J].北京中医药大学学报,2002,25(5)：49.
[15]商洪才,张伯礼.中医中风病危险因素及先兆症(证)研究系统评[J].中国中医药信息杂志,2002,(9)：3.
[16]冉志军.中医对脑血管病高位因素的认识[J].辽宁中医药大学学报,2008,10(6)：
12-13.
[17]赵海滨,左俊岭.中风先兆高危因素的调查分析[J].上海中医药杂志,2002,36(10)：11-12.
[18]黄慧敏,王涛.炎症、动脉粥样硬化与缺血性卒中.国际脑血管病杂志,2007,15(6)：464.
[19]刘冉,郝洪军,孙伟平等.血清炎性标志物与缺血性脑血管病的关系[J].中国神经免疫学和神经病学杂志,2009,16(2)：128.
[20]田海军,马燕妮,李朝武.影响脑梗死患者预后的相关因素分析及血尿酸检测的意义[J].白求恩医学院学报,2007,5(1)：5.
[21]谈晓牧,刘建国,耿晓坤等.高同型半胱氨酸血症对缺血性脑卒中患者再发及死亡预后影响的随访研究[J].中国神经免疫学和神经病学杂志,2009,16(5)：325.
[22]胡英嗣.脑卒中患者血清LP(a)水平与病情及预后的关系[J].Modern PracticalMedicine,2003,15(7)：422.
[23]周永,黄怀宇,朱向阳.缺血性卒中早期神经功能恶化的临床特征和危险因素分析[J].南通大学学报,2007,27(5)：362.
[24]杜敢琴,黄丽娜,富奇志等.脑卒中预后的影响因素分析[J].中华神经医学杂志,2005,4(1)：57.
[25]丁则昱,李晓光,崔丽英等.影响脑梗死远期预后的各风险指标分析[J].中国卒中,2006,1(3)：183.
[26]赵丽宏,韩杰.缺血性脑卒中病因分型与临床预后的关系[J].中华老年心脑血管病杂志,2009,11(6)：428.
[27]刘学东.缺血性脑卒中预后及其影响因素的研究[D].西安：流行病与卫生统计学,2007.
[28]陈瑞珍,吴慧堑,陈晓君.缺血性脑卒中就诊时间对患者预后的影响及护理对策[J].现代临床护理,2009,8(1)：23.
[29]杨翠英,郑华光,王立英等.代谢综合征对急性脑梗死早期预后的影响[J].中国卒中杂志,2007,2(7)：581.
[30]SU Yongjing, ZHANG zhenlu, ZHANG Xiaoyan, et al. New-Onset constiPation after stroke:incidence, risk factors and imPact on the Prognosis of stroke[J]. Chin J Ment Dis:2006,32 (4):300.
[31]范文可,胡永善,陈文华等.影响脑卒中患者发病后6个月时综合功能的多因素分析[J].中华物理医学与康复杂志,2008,30(3)：176.
[32]郑杰,田瑞振,刘德山.动脉粥样硬化的中医致病论初探[J].云南中医学院学报,2008,31(2)：28-29.
[33]程翔,廖玉华.炎症与动脉粥样硬化[J].中华心血管病杂志,2004,32(5)：475-
477.
[34]赵胜,刘伏元.特异性免疫与动脉粥样硬化[J].心血管康复医学杂志,2008,1(6)：595.
[35]张韶辉,高东升.动脉粥样硬化与炎症及药物应用研究进展[J].心血管病学进展2007,28(6)：947.
[36]马琳.益气活血法治疗缺血中风恢复期30例小结[J].中医中药,2007,45(21)：76.
[37]董道明,秦振华.育阴通络法在中风恢复期的应用体会[J].甘肃中医,2005,18(11)：28.
[38]常富业,王永炎.中风病毒邪论[J].北京中医药大学学报,2004,27(1)：3-6.
[39]王志菲,唐希灿.脑缺血损伤的炎症反应及治疗策略展望[J].中国新药与临床杂志,2007,26(6)：454-455.
[40]周明学,徐浩,潘琳等.活血、益气、化痰中药对APoE基因敲除小鼠主动脉粥样硬化斑块炎症反应的影响[J].中国中医急症,2008,17(4)：496.
[41]张京春,陈可冀.瘀毒病机与动脉粥样硬化易损斑块相关的理论思考[J].中国中西医结合杂志,2008,28(4)：368.
[42]贾冬,杜佳林,向绍杰等.消栓通络精制胶囊药效学实验研究[J].中国中药杂志,2007,32(12)：1244.
[43]许宏霞,曹晓岚,王敏.对缺血性中风病急性期炎症反应的中西医认识[J].中西医结合心脑血管病杂志,2007,5(2)：156.
[44]HUANG J, UPADHYAY UM, TAMARGO RJ. Inflammation in stroke and focal cerebral ischemia[J].Surg Neurol,2006.66(3):232-245.
[45]ZHANG RL, CHOPP M, JIANG N, et al. Anti-intercellular adhesion mole cule-1 antibody reduces ischemic cell damage after transient but not P ermanent middle cerebral artery occlusion in the Wistar rat[J]. Stroke,1995,26(8): 1438-1442.
[46]MASADA T, HUA Y, Xl G, et al. Attenuation of intracerebral hemorrha ge and thrombin-induced brain edema by overexPression of interleukin-1 recePtor antagonist[J]. J Neurosurg,2001,95(4):680-686.
[47]KAWA1 N, OKAUCH1 M, MORISAKI K, et al. Effects of delayed intraische mic and Postischemic hyPothermia on a focal model of transient cerebral ischemia in rats[J]. Stroke,2000,31(8):1982-1989.
[48JBOROVIKOVA LV, IVANOVA S, ZHANG M, et al. Vagus nerve stimulation att enuates the systemic inflammatory resPonse to endotoxin[J]. Nature,2000,405 (6785):458-462.
[49]PAVLOV VA, WANG H, CZURA CJ, et al.The cholinergic anti-inflammato ry Pathway:a missing link in neuroimmunomodulation[J]. Mol Med,2003,9(5-8): 125-134.
[50]TRACEY KJ. The inflammatory reflex[J]. Nature,2002,420(6917):853-859.
[51]TRACEY KJ, CZURA CJ, IVANOVA S.Mind over immunity[J]. FASEB J,2001, 15(9):1575-1576.
[52]CZURA CJ, FRIEDMAN SG, TRACEY KJ. Neural inhibition of inflammation:the cholinergic anti-inflammatory Pathway[J].J Endotoxin Res,2003,9(6): 409-413.
[53]马斌,高颖.脑卒中结局评价及建立病证结合临床评价模式的研究设想[J].中国临床康复,2006,35(10)：155.
[54]张伯礼,王玉来,高颖等.中风病急性期综合治疗方案研究与评价—附522例临床研究报告[J].中国危重病急救医学,2005,17(5)：263.
[55]老鹰荣,郭新峰,赖世隆等.不同维度多个量表对脑卒中恢复期评价的比较[J].中国临床康复,2005,9(29)：7.
[56]张振强,荆志伟,周红霞等.用世界卫生组织生存质量量表评价中风患者的生存质量[J].中国中医药信息杂志,2005,12(11)：18.
[57]高颖,马斌.中风病结局评价及病证结合临床评价标准的研究[C].中华中医药学会内科分会2007年学术年会论文集,2007,11：76.
[58]FruhwaldS, RelationshiP between dePression, anxiety and quality of life: A study of stroke Patients comPared to chronic low back Pain a nd myocardial ischemia Patients[J]. PsychoPathology,2001,34(1):5.
[59]张跃文,杨传东,周凤龙.中风中西医疗效评价之比较[J].中国社区医师·医学专业半月刊,2008,10(1)：9.
[60]金杰.中医治疗缺血性中风124例疗效对比观察[J].河南中医,2004,25(10)：42.
[61]Duncan PW, Jorgensen HS, Wade DT. Outcome measures in acute stroke trials: a systematic review and some recommendations to imProve Practice[J]. Stroke,2000,31(6):1434.
[62]杨鹏远,芮耀诚,焦亚斌.动脉粥样硬化大鼠实验模型的建立[J].第二军医大学学报,2003,24(7)：802-803.
[63]顾国军,黄振兴,陶凯忠等.HBO对内皮素-1诱导的大鼠局灶性脑缺血模型的疗效观察[J].第二军医大学学报,2006,27(10)：1135.
[64]吴浩,吉训明,赵喜庆等.改良大鼠MCAO模型的建立[J].中华实验外科杂志,2006,23(12)： 1554.
[65]许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4)：230.
[66]刘茂才,黄燕,卢明.中医脑病临证证治[M].广东.广东人民出版社,2006,1：110-122.
[67]刘英芹.粘附分子与缺血性脑损伤的研究进展[J].国外医学临床生物化学与检验学分册,2005,26(10)：703-704.
[68]庞霞,李平.炎症与不稳定动脉粥样硬化斑块[J].医学综述,2008,14(4)：539.
[69]孙平,陈文强,李宗信等.中西医干预动脉粥样硬化ICAM-1表达的研究进展[J].安徽中医学院学报,2007,26(3)：62.
[70]DaviesMJ, Gordon Gearing AJ. The exPression of the adhesion molecule ICAM-1, VCAM-1, PECAM-1 and E-selectin in human atherogenesis[J]. J Pathol ,1993,171(3):223-229.
[71]Daniel S The neuroPathology and neurochemistry of multiP le system atroPhy. InMathias C, Bannister R, eds Autonomic failure atextbook of clinical disorders of the autonomic nervous system[M]. Oxford:Oxford University Press,1999:321-328.
[72]DeGraba TJ, Siren AL, Penix L, et al. Increased Endothelial ExPression of Interce-llular Molecule-1 in SymPtomatic Versus AsymP tomatic Human Caro-tid Athero-sclerotic Plaque[J]. Stroke,1998,29(7):1405-1410.
[73]AsanoriAikawa, Peter Libby. The vulnerable atherosclerotic Plaque:Pathohen-esis and theraPeutic aPProach [J]. Cardio Vascular Pathology,2004,13(3): 125-138.
[74]Nageh MF, Sandberg ET, Marotti KR, et al. Deficiency of inflammatory cell adhesion molecules Protects against atherosclerosis in mice[J].Arterio-scler Thromb Vasc Biol,1997,17(8):1517-1520.
[75]付素洁,邱伟庆,尤可.中风恢复期病机及辨治进展[J].河南中医学院学报,2005,20(5)：86-87.
[76]祝维峰,周迎春,冯学功等.邵念方教授治疗中风病特色浅述[J].中国中医急症,1997,6(6)：274-275.
[77]Li JC, Zhou HD, Deng J, Wang YJ, Zhang M. A study of relation between changes in serum soluble intercellular adhesion molecule and infarction volume in Patients with acute cerebral infarction. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue[J].2008,20(11):660-2.
[78]Rallidis LS, Zolindaki MG, Vikelis M, Kalivak, et al. Elevated soluble inter-cellular adhesion molecule-1 levels are associated with Poor short-term
Prognosis in middle-aged Patients with acute ischaemic stroke. Int J Car-diol[J].2009,132(2):216-20.
[79]Simundic AM, Basic V, ToPic E, et al. Soluble adhesion molecules in acute ischemic stroke. Clin Invest Med [J].2004,27(2):86-92.
[80]蔡洪信,郝芳,夏作理.ICAM-1与脑缺血再灌注损伤研究进展.中国微循环[J].2005,9(5)：364.
[81]陈燕,陈慧.基质金属蛋白酶-9与易损斑块[J].心血管康复医学杂志,2007,16(1)： 96.
[82]王强,王毅.通脉胶囊对动脉粥样硬化斑块稳定性影响的实验研究[J].中成药,2004,26(9)：734.
[83]刘金来,朱强锋,郝宝顺.通心络血清对U937单核巨噬细胞MMP-9及TIMP-1表达与分泌的影响[J].南方医科大学学报,2008,28(9)：1706.
[84]金华.和中化痰活血法治疗缺血性中风恢复期及后遗症期的临床研究[J].甘肃中医,2000,13(3)：55-57.
[85]Yallg Y, Estrada EY, ThomPson JF, et al. Matrix metalloProteinasemediated disruption of tight junction Proteins in cerebral vessels is reversed by synthetic matrix melalloProteinase inhibitor in focal ischemia in rat[J]. J Cereb Blood Flow Metab,2007,27:697-709.
[86]麻志恒,魏国俊.中风恢复期从脾论治[J].甘肃中医学院学报,2001,18(1)：10-11.
[87]顾晔,刘振国.MMP-9与脑梗死出血性转化及研究进展[J].中国临床神经科学2008,16(4)：428.
[88]Lucivero V, Prontera M, MezzaPesa DM, et al. Different roles of matrix metalloProteinases-2 and-9 after human ischaemic stroke[J]. Neurol Sci, 2007,28:165-170.
[89]Rosell A, Alvarez-Sabin J, Arenillas JF, et al. A matrix metalloProteinase Protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human [J]. Stroke,2005, 36:1415-1420.
[90]Barr TL, Latour LL, Lee KY, et al. Blood-brain barrier disruPtion in humans is indePendently associated with increased matrixmetalloProteinase-9[J] .Stroke,2010,41(3):123-8.
[91]陶定波,姜秀丽,雷阳等.血清基质金属蛋白酶9和组织基质金属蛋白酶抑制剂1与急性脑梗死的临床关系[J].中华老年心脑血管病杂志,2009年10月第11卷第10期：777.
[92]冯民,张梅,张运等.吸烟与动脉粥样硬化的关系[J].中国动脉硬化杂志,2006,14(11)：1006.